Clinical Journal of Gastroenterology

, Volume 4, Issue 4, pp 185–197

Chemoprevention against hepatocellular carcinoma

  • Jun-ichi Okano
  • Yuki Fujise
  • Ryo Abe
  • Ryu Imamoto
  • Yoshikazu Murawaki
Clinical Review

DOI: 10.1007/s12328-011-0227-8

Cite this article as:
Okano, J., Fujise, Y., Abe, R. et al. Clin J Gastroenterol (2011) 4: 185. doi:10.1007/s12328-011-0227-8

Abstract

Since the majority of hepatocellular carcinoma (HCC) arises from a background of chronic liver diseases caused by infection with hepatitis C virus (HCV) and hepatitis B virus (HBV), chemoprevention targeting patients at high risk of HCC is feasible. In this review article, we summarize current knowledge of chemoprevention against HCC mostly using phytochemicals which have less toxicity than pharmaceutical agents. We describe in vivo and in vitro evidence and proposed mechanisms of beneficial effects of several compounds on the liver, including acyclic retinoid (ACR), angiotensin-converting enzyme inhibitors (ACEIs), caffeine, capsaicin, cepharanthine (CEP), cinnamaldehyde, curcumin, diallyl sulfide (DAS), eicosapentaenoic acid (EPA), epigallocatechin-3-gallate (EGCG), genistein, lycopene, resveratrol, silymarin, sulforaphane (SFN), and xanthohumol (XN). Because antihepatocarcinogenic effects by these compounds are mostly based on experimental studies, clinical evidence is urgently necessary.

Keywords

Hepatocellular carcinomaChemopreventionPhytochemicals

Abbreviations

AP-1

Activator protein 1

ACR

Acyclic retinoid

AFP

Alpha-fetoprotein

ACEI

Angiotensin-converting enzyme inhibitor

ARE

Antioxidant responsive element

b-FGF

Basic fibroblast growth factor

BCAAs

Branched-chain amino acids

CEP

Cepharanthine

COX-2

Cyclooxygenase-2

DAS

Diallyl sulfide

DEN

Diethylnitrosamine

EPA

Eicosapentaenoic acid

EGCG

Epigallocatechin-3-gallate

ERK1/2

Extracellular signal-regulated kinase 1/2

FAP

Familial adenomatous polyposis

FAS

Fatty acid synthase

GST

Glutathione S-transferase

GSK

Glycogen synthase kinase

HSP

Heat shock protein

HBV

Hepatitis B virus

HCV

Hepatitis C virus

HCC

Hepatocellular carcinoma

HMG-CoA

3-Hydroxy-3-methyl-glutaryl coenzyme A reductase

IGF-1R

Insulin-like growth factor-1 receptor

IFN

Interferon

JNK

c-Jun NH2-terminal kinase

Keap1

Kelch-like ECH-associated protein 1

MMP

Matrix metalloproteinase

MAPK

Mitogen-activated protein kinase

mTOR

Mammalian target of rapamycin

MTT

Molecular targeted therapy

NASH

Nonalcoholic steatohepatitis

Nrf2

NF-E2-related factor 2

NOS

Nitric oxide synthase

NDEA

N-nitrosodiethylamine

NF-kappaB

Nuclear factor-kappaB

PEIT

Percutaneous ethanol injection

PTEN

Phosphatase and tensin homolog

PDGF

Platelet-derived growth factor

PUFA

Polyunsaturated fatty acid

PIVKA-II

Protein induced by vitamin K absence or antagonist

RFA

Radiofrequency ablation

RAS

Renin–angiotensin system

SFN

Sulforaphane

STAT

Signal transducer and activator of transcription

hTERT

Telomerase reverse transcriptase

Trx

Thioredoxin

TNF

Tumor necrosis factor

TACE

Transarterial chemoembolization

TRAIL

Tumor necrosis factor-related apoptosis-inducing ligand

VEGF

Vascular endothelial growth factor

XN

Xanthohumol

Copyright information

© Springer 2011

Authors and Affiliations

  • Jun-ichi Okano
    • 1
  • Yuki Fujise
    • 1
  • Ryo Abe
    • 1
  • Ryu Imamoto
    • 1
  • Yoshikazu Murawaki
    • 1
  1. 1.Second Department of Internal MedicineTottori University School of MedicineYonagoJapan